The farnesoid X receptor (FXR) is a member of the
nuclear receptor superfamily that regulates
bile acid homeostasis. It is expressed in the liver and the gastrointestinal tract, but also in several non-enterohepatic tissues including testis. Recently, FXR was identified as a negative modulator of the
androgen-
estrogen-converting
aromatase enzyme in human
breast cancer cells. In the present study we detected the expression of FXR in Leydig normal and tumor cell lines and in rat testes tissue. We found, in rat Leydig
tumor cells, R2C, that FXR activation by the primary
bile acid chenodeoxycholic acid (CDCA) or a synthetic agonist
GW4064, through a SHP-independent mechanism, down-regulates
aromatase expression in terms of
mRNA,
protein levels, and its enzymatic activity. Transient transfection experiments, using vector containing rat
aromatase promoter PII, evidenced that CDCA reduces basal
aromatase promoter activity. Mutagenesis studies, electrophoretic mobility shift, and
chromatin immunoprecipitation analysis reveal that FXR is able to compete with
steroidogenic factor 1 in binding to a common sequence present in the
aromatase promoter region interfering negatively with its activity. Finally, the FXR-mediated anti-proliferative effects exerted by CDCA on
tumor Leydig cells are at least in part due to an inhibition of
estrogen-dependent cell growth. In conclusion our findings identify for the first time the activators of FXR as negative modulators of the
aromatase enzyme in Leydig tumor cell lines.